GlassScriptPhysician profile
Trever Sinjin Symalla
NPI 1801283270
$716.48
in general payments reported to CMS, 2019-2025
14 companies · $75.88 in 2025
The $75.88 reported for 2025 was less than what a typical Surgery provider received nationally (typical 2025 total: $281).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $101 · 2020: $305 · 2022: $19.54 · 2023: $146 · 2024: $68.74 · 2025: $75.88.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $291.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $290.69 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Medical Device Business Services, INC. | $305.00 | 2020 | |
| Medtronic Vascular, INC. | $101.25 | 2019 | |
| E.R. Squibb & Sons, L.L.C. | $41.98 | 2023-2024 | Opdivo |
| Astrazeneca Pharmaceuticals LP | $41.31 | 2023 | Lynparza, Imfinzi |
| Musculoskeletal Transplant Foundation INC. | $32.06 | 2023 | |
| Daiichi Sankyo INC. | $29.47 | 2024 | Enhertu |
| Medtronic, INC. | $29.15 | 2025 | Ligasure |
| Karl Storz Endoscopy-America | $26.75 | 2025 | Na |
| Celgene Corporation | $21.51 | 2023 | Opdualag |
| Boston Scientific Corporation | $19.98 | 2025 | Spyglass Discover |
| Merck Sharp & Dohme LLC | $19.54 | 2022 | |
| Avanos Medical | $17.68 | 2023 | On-Q* Pump and Accessories |
| Incyte Corporation | $15.83 | 2023 | Pemazyre, Monjuvi |
| Ipsen Biopharmaceuticals, INC | $14.97 | 2024 | Onivyde |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Trever Symalla listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.